Literature DB >> 11081176

The therapeutic value of somatostatin and its analogues.

S Farooqi1, J S Bevan, M C Sheppard, J A Wass.   

Abstract

In this review we discuss the physiological effects of somatostatin, which are mediated by specific receptor subtypes on different tissues. These observations have suggested new therapeutic possibilities for the use of the synthetic somatostatin analogues in the treatment of acromegaly as well as a number of other endocrine and non-endocrine disorders.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 11081176     DOI： 10.1023/a:1009978106476

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   4.107


  90 in total

Review 1.  Peptides in the brain: the new endocrinology of the neuron.

Authors:  R Guillemin
Journal:  Science       Date:  1978-10-27       Impact factor: 47.728

Review 2.  Oncological applications of somatostatin analogues.

Authors:  A V Schally
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

Review 3.  Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

Authors:  J C Gillis; S Noble; K L Goa
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 4.  Distribution of somatostatin receptors in normal and tumor tissue.

Authors:  J C Reubi; L Kvols; E Krenning; S W Lamberts
Journal:  Metabolism       Date:  1990-09       Impact factor: 8.694

5.  Hyperthyroidism with elevated plasma TSH levels and pituitary tumor: study with somatostatin.

Authors:  E Reschini; G Giustina; M Cantalamessa Lperacchi
Journal:  J Clin Endocrinol Metab       Date:  1976-10       Impact factor: 5.958

6.  In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue.

Authors:  J C Reubi; B Waser; U Horisberger; E Krenning; S W Lamberts; J O Gebbers; P Gersbach; J A Laissue
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

Review 7.  Gallstones during octreotide therapy.

Authors:  R H Dowling; S H Hussaini; G M Murphy; G M Besser; J A Wass
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694

Review 8.  Emerging indications for octreotide therapy, Part 1.

Authors:  K W Mosdell; J A Visconti
Journal:  Am J Hosp Pharm       Date:  1994-05-01

9.  The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.

Authors:  A J van der Lely; A G Harris; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1992-08       Impact factor: 3.478

10.  Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome.

Authors:  G M Prelević; M I Wurzburger; L Balint-Perić; P Hardiman; S Okolo; D Maletić; J Ginsburg
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694
View more
  2 in total

1.  The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation.

Authors:  Erika Peverelli; Giovanna Mantovani; Davide Calebiro; Andrea Doni; Sara Bondioni; Andrea Lania; Paolo Beck-Peccoz; Anna Spada
Journal:  Mol Endocrinol       Date:  2007-12-20

2.  Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.

Authors:  P Kendall-Taylor; M Miller; J Gebbie; S Turner; M al-Maskari
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.